Labroots

Measurable Residual Disease in AML using Oncomine NGS analysis

The presentation "Measurable Residual Disease in AML using Oncomine NGS analysis" by Dr. Jong-Mi Lee from the College of Medicine at The Catholic University of Korea explores the application of ...
The Scientist

Bridging Genes and Disease with NGS-Based Proteomics

Genomics offers a foundation for understanding disease, but proteomics reveals invaluable insights by offering a real-time look at protein activity. Proteogenomic studies are advancing thanks to ...
Nature

Multi-target measurable residual disease assessed by error-corrected sequencing in patients with acute myeloid leukemia: An ALFA study

Acute myeloid leukemia (AML) is an aggressive malignancy that emerges from the accumulation of genetic events in hematopoietic stem or early progenitor cells [1,2,3]. The mutational landscape of AML ...
Nature

Clinical implementation of next-generation sequencing testing and genomically-matched therapy: a real-world data in a tertiary hospital

The last decade has seen a significant shift in how patients with cancer are diagnosed and managed through the clinical application of next-generation sequencing (NGS) technology. Large-scale tumor ...
ascopubs.org

Enhanced Detection of Druggable Mutations in Non–Small Cell Lung Cancer Using Targeted Collection of Bronchial Washing Fluid Compared With Plasma and Tumor Tissue

All study participants simultaneously underwent NGS using three sample types: (1) BWF, (2) plasma, and (3) tumor tissue collected during bronchoscopy. The full patient set (FPS) included all enrolled ...